You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中基長壽科學(00767.HK)擬收購浙江艾明德生物科技51%或以上股權
格隆匯 08-18 21:06

格隆匯8月18日丨中基長壽科學(00767.HK)公吿,於2021年8月18日,公司與浙江艾明德生物科技有限公司("目標公司")所有股東(包括卓信投資控股(深圳)有限公司、朱炎、朱霞等,統稱"賣方")訂立諒解備忘錄,據此,公司有意向目標公司所有股東提出收購其所持有目標公司的51%或以上股權。

目標公司於2017年在中國註冊成立的有限公司,是一家致力於體外診斷試劑和儀器、微結構光學器件和光電信號處理技術為核心的集研發、生產、銷售為一體的高科技企業。根據賣方提供的資料,目標公司於2020年實現銷售收入6.5億元人民幣,並於2021年4月1日與買家ElkayPlasticsCo.Inc通過買家代理TheMedicalSupplyCompanyofSwitzerland(MSCS)簽訂10,800萬美元的訂單。

董事會相信潛在收購可進一步完善集團全球長壽科學領域的佈局,進一步提升集團在長壽醫學領域的領先地位,長遠為集團帶來穩定、持續增長收入。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account